industry, and other stakeholders. Through its work, Syndicate Bio is making local impact while accelerating drug discovery and development. By focusing on Africa, Syndicate Bio is poised to make a significant impact, starting with Nigeria, by...
Kiromic BioPharma, Inc. reports early efficacy results showing tumor stabilization in the third patient enrolled in the Company’s Deltacel-01 Phase 1 clinical trial. Deltacel-01 is evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic....
Neurocrine Biosciences, Inc. announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1065890 in healthy adult participants. NBI-1065890 is...
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, announced three poster presentations at the 2024...
a check mark secured on both the formulation technology and the pharmacological mode of action established in early drug discovery, we are confident in the ongoing success of TPT0701 as it progresses through development," added Morten Allesø....
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large...
by multiple measures. Key features of MASH are conserved in the tissue and allow for superior disease understanding, drug discovery and development. MASH is the new clinical term introduced in 2023 to replace NASH (non-alcoholic steatohepatitis)....
